SIFI is a leading international company in the ophthalmic field, based in Italy, specialized in eye care since 1935. SIFI develops, manufactures and markets innovative therapeutic solutions for patients with ophthalmic diseases. SIFI is fully committed through its research and development to improve the quality of life of patients, exporting to more than 20 countries around the world with a direct presence in Italy, Spain, France, Romania, Mexico, Turkey.
CAMI is a multidisciplinary reality created to serve, through an active and healthy lifestyle, the entire cycle of life, from pre-natal to the third age.
| company deafness center, in the health sector; we deal with hearing aids, cochlear implants, everything related to the auditory system., ears. |
The Institute of Crystallography Catania Unit of Research National Council (CNR-IC-CT) uses skills in the field of chemistry and biology aimed at studying the molecular mechanisms that underlie numerous human diseases for the development of new "tools " for prevention, diagnosis and therapies. The institute is characterized by many specific skills in the fields of chemistry (synthesis, physics-chemistry, analytical chemistry, thermodynamics) and biology (molecular biology, biochemistry, cell biology).
Fidia Farmaceutici S.p.A. is an Italian pharmaceutical company that carries out R&D, production, marketing and sales activities internally. It operates all over the world with the aim of developing and marketing innovative health products based mainly on hyaluronic acid and derivatives. It invests 3.5% of its turnover in R&D and has a global portfolio of over 1,300 patents. The Noto Local Unit occupies about 6,000 square meters with R&D, biology, microbiology, molecular and analytical biology laboratories.
ECLAT S.r.l. is a research based company with a high technological content specialized in the sector of combustion-free devices that can replace the traditional cigarette with clear benefits for health. Established in July 2018 as a spin off of the University of Catania, on the proposal of Prof. Riccardo Polosa, within the Department of Clinical and Experimental Medicine, ECLAT was born from the desire to enhance, concentrate and harmonize skills and professionalism that have developed in the academic, regulatory and industrial fields on the topic of cigarette smoking risk reduction.
| The office of Prof. Dr. Carmelo Giuffrida is an independent organization with a design approach dedicated exclusively to the Sciences of the Human Movement and to all related sectors. Using mainly scientific research and development projects and in collaboration with prestigious technical, educational and university partners, it supports the future of Human Movement Sciences and constantly develops methods and techniques concerning the Physiology of Physical Exercise, Posturology, Applied Biomechanics, Rehabilitative Kinesiology. |
Vera Salus Ricerca S.r.l. (VSR) is a biotechnology discovery company specialized in translational biomedical research aimed at the development of innovative drugs for the treatment of human diseases, with a particular focus on incurable diseases. VSR has also devised a new business model that is based on the technological transfer of ownership through innovative development paths, tailor-made for each type of company-client in the biotech world, with the aim of creating new products or processes that increase them. competitiveness on the market strongly.
Materia Nova, R&D center located in Mons, is recognized as a technological accelerator of sustainable innovations in the field of new materials and processes.
OUR SERVICES
Materia Nova's approach is based on open and collaborative innovation articulated around five services :
• Materials and Processes conception and innovation • Equipment Design and Process Upscaling • Analysis and Characterization
• Life Cycle Thinking
• Project Development and Management
OUR TECHNOLOGIES AND SOLUTIONS
Ahead Together
We unite science, technology and talent to get ahead of disease together. We are committed to doing the right thing and we aim to positively impact the health of 2.5 billion people by the end of 2030. We’ll do this by bringing together outstanding people and doing work that matters in an inclusive environment, so we can make an impact on a global scale.